Drug Ther Bull. 1995 Dec;33(12):92-3. doi: 10.1136/dtb.1995.331292.
Co-trimoxazole, the fixed-dose preparation of trimethoprim (80mg) plus sulphamethoxazole (400mg), has been available in the UK since 1969. At its launch the Drug and Therapeutics Bulletin accepted the logic of using the combination but advised prescribers to be alert to the possibility of unwanted effects. In 1980 we advised that, in some infections, a single antibiotic might be at least as effective as co-trimoxazole, with a lower risk of unwanted effects. Later that year, when trimethoprim became available alone, we recommended it should be used in the place of co-trimoxazole for uncomplicated infections of the urinary tract, advice we repeated in 1986. In July of this year, the licensed indications for co-trimoxazole were narrowed and now reflect many of our earlier recommendations. In this article we review the history of co-trimoxazole, discuss the recent licensing changes and ask when the drug should be used in clinical practice.
复方新诺明是甲氧苄啶（80毫克）与磺胺甲恶唑（400毫克）的固定剂量复方制剂，自1969年起在英国上市。该药上市时，《药物与治疗通报》认可使用该复方制剂的合理性，但建议处方医生留意不良反应的可能性。1980年我们建议，在某些感染中，单一抗生素可能至少与复方新诺明一样有效，且不良反应风险更低。同年晚些时候，当甲氧苄啶单独上市时，我们推荐用其替代复方新诺明治疗非复杂性尿路感染，1986年我们再次给出此建议。今年7月，复方新诺明的许可适应证范围缩小，如今反映了我们之前的许多建议。在本文中，我们回顾复方新诺明的历史，讨论近期的许可变更情况，并探讨该药物在临床实践中何时应使用。
